title: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.
abstract: Antisense oligonucleotides are being evaluated in clinical trials as novel therapeutic agents. To further improve the properties of antisense oligonucleotides, we have designed mixed-backbone oligonucleotides (MBOs) that contain phosphorothioate segments at the 3' and 5' ends and have a modified oligodeoxynucleotide or oligoribonucleotide segment located in the central portion of the oligonucleotide. Some of these MBOs indicate improved properties compared with phosphorothioate oligodeoxynucleotides with respect to affinity to RNA, RNase H activation, and anti-HIV activity. In addition, more acceptable pharmacological, in vivo degradation and pharmacokinetic profiles were obtained with these MBOs.
authors.affiliation: Hybridon Inc., Cambridge, MA 02139, USA.
authors.forename: S
authors.initials: S
authors.lastname: Agrawal
authors.forename: Z
authors.initials: Z
authors.lastname: Jiang
authors.forename: Q
authors.initials: Q
authors.lastname: Zhao
authors.forename: D
authors.initials: D
authors.lastname: Shaw
authors.forename: Q
authors.initials: Q
authors.lastname: Cai
authors.forename: A
authors.initials: A
authors.lastname: Roskey
authors.forename: L
authors.initials: L
authors.lastname: Channavajjala
authors.forename: C
authors.initials: C
authors.lastname: Saxinger
authors.forename: R
authors.initials: R
authors.lastname: Zhang
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D001483:Base Sequence; D001777:Blood Coagulation / Q000187:drug effects; D002460:Cell Line; D002478:Cells, Cultured; D015195:Drug Design; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D009691:Nucleic Acid Denaturation; D009838:Oligodeoxyribonucleotides; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology*; D009843:Oligoribonucleotides; D051381:Rats; D017207:Rats, Sprague-Dawley; D016914:Ribonuclease H / Q000378:metabolism*; D013154:Spleen; D013873:Thionucleotides; D014227:Triazines; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D019380:Anti-HIV Agents; D009838:Oligodeoxyribonucleotides; D016376:Oligonucleotides, Antisense; D009843:Oligoribonucleotides; D013873:Thionucleotides; D014227:Triazines; C053507:4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine; D016914:Ribonuclease H